We have all seen the Lipitor commercials with Dr. Robert Jarvik (he is not licensed to practice medicine in any state, but went to medical school) touting the cholesterol lowering benefits of that drug.
In fact, the company claims it will lower bad cholesterol by 39-60%:

The average consumer reading this rightfully thinks this is a good thing for your health. The question, though, is what is the real significance of lowering bad cholesterol.
Another Lipitor ad helps explain this too:

So, for people at risk, taking Lipitor lowers your chances of having a heart attack by 36%. This certainly sounds like a big benefit for most people considering taking this drug, until you look at the fine print:
*MOUSE PRINT:

The company apparently conducted a test whereby high risk people were divided into two groups, one of which got Lipitor, and the other got a placebo. Out of every 100 subjects tested, only three people who in essence took nothing to lower their cholesterol suffered heart attacks. On the other hand, two out of 100 Lipitor takers had a heart attack. The difference, according to the study, is that for every 100 people who take Lipitor, only one additional person will be spared a heart attack compared to those who do nothing.
So despite the big percentage claims made in advertising — 39% to 60% reduction in bad cholesterol, and 36% reduction in risk of heart attacks — if the risk the pill is reducing is very small to start with, very few people will actually be spared that heart attack by taking Lipitor (but the company will make a lot of money in the process).
Of course, for the one person in a hundred who is spared, the pill is priceless.
For more information on the math used in drug advertising, read this Business Week story.
Since the beginning of January, owners of Quicken 2005 have been bombarded with reminders (via pop-ups when starting up the software, and by mail) that on April 30, 2008 many important features of the program will stop functioning. Mouse Print* this week will examine the stark contrast between these current elaborate disclosures and how poorly new customers are warned before purchase that the software will become substantially disabled in three years.


As we approach tax time, many consumers are in the market for new tax prep software and may at the same time upgrade their financial management program such as Quicken. The bad news is that the combination deals of past years where one could get Quicken Basic free after rebate when purchasing TurboTax are all but gone. The replacement offer is less generous than it appears to be because of details in the fine print, and a change of corporate philosophy.